UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Mitotane has a strong and a durable inducing effect on CYP3A4 activity

European journal of endocrinology, 2011-04, Vol.164 (4), p.621

2011

Volltextzugriff (PDF)

Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients

Therapeutic drug monitoring, 2009-04, Vol.31 (2), p.187

2009

Volltextzugriff (PDF)

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

DRUG METABOLISM AND PHARMACOKINETICS, 2009-01, Vol.24 (1), p.3-15

2009

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

Anesthesiology (Philadelphia), 2009, Vol.110 (1), p.95-105

2009

Volltextzugriff (PDF)

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Clinical and translational science, 2019-09, Vol.12 (5), p.459-469

2019

Volltextzugriff (PDF)

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

Journal of clinical pharmacology, 2013-03, Vol.53 (3), p.256-263

2013

Volltextzugriff (PDF)

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

British journal of clinical pharmacology, 2020-12, Vol.86 (12), p.2362-2376

2020

Volltextzugriff (PDF)

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation

British journal of clinical pharmacology, 2022-02, Vol.88 (2), p.734-741

2022

Volltextzugriff (PDF)

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

European journal of cancer (1990), 2021-08, Vol.153, p.142-152

2021

Volltextzugriff (PDF)

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

Epilepsia (Copenhagen), 2009-01, Vol.50 (1), p.88-98

2009

Volltextzugriff (PDF)

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Trends in pharmacological sciences (Regular ed.), 2008-04, Vol.29 (4), p.186-191

2008

Volltextzugriff (PDF)

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

Drug discovery today, 2013-09, Vol.18 (17-18), p.853-862

2013

Volltextzugriff (PDF)

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

EClinicalMedicine, 2023-04, Vol.58, p.101917-101917, Article 101917

2023

Volltextzugriff (PDF)

Model‐Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms

Journal of clinical pharmacology, 2017-05, Vol.57 (5), p.640-651

2017

Volltextzugriff (PDF)

Mechanism-based pharmacokinetic -pharmacodynamic modeling : Biophase distribution, receptor theory, and dynamical systems analysis

Annual review of pharmacology and toxicology, 2007-01, Vol.47 (1), p.357-400

2007

Volltextzugriff (PDF)

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Journal of pharmacological and toxicological methods, 2013-05, Vol.67 (3), p.203-213

2013

Volltextzugriff (PDF)

Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration

Drug metabolism and disposition, 2011-12, Vol.39 (12), p.2275

2011

Volltextzugriff (PDF)

Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation

Drug metabolism and disposition, 2014-09, Vol.42 (9), p.1367

2014

Volltextzugriff (PDF)

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach

The Journal of pharmacology and experimental therapeutics, 2017-02, Vol.360 (2), p.356

2017

Volltextzugriff (PDF)

Exploring genetic and non‐genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients

British journal of clinical pharmacology, 2016-07, Vol.82 (1), p.227-237

2016

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography

Molecular imaging and biology, 2005-11, Vol.7 (6), p.411-421

2005

Volltextzugriff (PDF)

Nonlinear Mixed Effects Modeling of the Diurnal Blood Pressure Profile in a Multiracial Population

American journal of hypertension, 2013-09, Vol.26 (9), p.1103-1113

2013

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Toxicology and applied pharmacology, 2000-02, Vol.162 (3), p.177-188

2000

Volltextzugriff (PDF)

Application of the Convection-Dispersion Equation to Modelling Oral Drug Absorption

Bulletin of mathematical biology, 2007-01, Vol.69 (1), p.181-195

2007

Volltextzugriff (PDF)

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silicoain vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Journal of pharmacological and toxicological methods, 2013-06, Vol.67 (3), p.203-213

2013

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology/toxicology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(50)
Buchkapitel
(1)

Sprache

Englisch
(51)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mitotane has a strong and a durable inducing effect on CYP3A4 activity

Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Model‐Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms

Mechanism-based pharmacokinetic -pharmacodynamic modeling : Biophase distribution, receptor theory, and dynamical systems analysis

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration

Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach

Exploring genetic and non‐genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients

Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography

Nonlinear Mixed Effects Modeling of the Diurnal Blood Pressure Profile in a Multiracial Population

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Application of the Convection-Dispersion Equation to Modelling Oral Drug Absorption

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silicoain vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Aktive Filter

Suchergebnisse filtern